Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILENT TECHNOLOGIES, INC.A · Entity 3062 | Director | March 19, 2026 | March 23, 2026 |
| EXELIXIS, INC.EXEL · Entity 3386 | Director | May 18, 2020 | May 21, 2020 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | February 24, 2025 | February 25, 2025 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILENT TECHNOLOGIES, INC.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,800.047 |
Reported balance
After 2026-03-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 2,158 · Balance 22,800.047 F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock. F2: 148.973 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 23,857.047 |
Reported balance
After 2026-03-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-19 · Grant · Acquired 1,057 · Balance 23,857.047 F3: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. |
| Common StockSEC Table I · non-derivative | IndirectGeorge A. Scangos and Leslie S. Wilson Family Trust | 17,893 |
Reported balance
Holding disclosure · report date 2026-03-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 17,893 F4: Shares held in the George A. Scangos and Leslie S. Wilson Family Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock.
F2: 148.973 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.
F3: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors.
F4: Shares held in the George A. Scangos and Leslie S. Wilson Family Trust.
EXELIXIS, INC.
Report date May 18, 2020 · Filed May 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 714,717 |
Reported balance
After 2020-05-18 transaction · row 1
1 source rowRow 1 · 2020-05-18 · Sale · Disposed 75,000 · Balance 714,717 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.59 to $26.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust (JS) | 8,963 |
Reported balance
Holding disclosure · report date 2020-05-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,963 F3: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Jennifer Scangos Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust (KS) | 8,963 |
Reported balance
Holding disclosure · report date 2020-05-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,963 F4: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Katherine Scangos Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,669 |
Reported balance
Holding disclosure · report date 2020-05-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,669 F5: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 18, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.
F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.59 to $26.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
F3: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Jennifer Scangos Trust.
F4: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Katherine Scangos Trust.
F5: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 18, 2020.
Vir Biotechnology, Inc.
Report date February 24, 2025 · Filed February 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 698,239 |
Reported balance
After 2025-02-24 transaction · row 1
1 source rowRow 1 · 2025-02-24 · Sale · Disposed 10,056 · Balance 698,239 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,151,730 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,151,730 F2: The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,151,730 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,151,730 F4: The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 33,629 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 33,629 F5: The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 179,930 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 179,930 F6: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 598,270 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 598,270 F3: The shares are held by the spouse of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F2: The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F3: The shares are held by the spouse of the Reporting Person.
F4: The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F5: The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
F6: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
Voyager Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2036-06-09 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:05 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001104659-26-072934 · tm2617547-9_4seq1.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:29 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,057 | $111.75 | $118,119.75 |
DisclosureSEC source: 0001090872-26-000036 · form4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,857.047 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:29 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 2,158 | $111.75 | $241,156.50 |
DisclosureSEC source: 0001090872-26-000036 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,800.047 F1 · price: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock. F2 · balance_after: 148.973 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:08 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001104659-25-056567 · tm2517191-8_4seq1.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 14:05 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,819 | $121.18 | $220,426.42 |
DisclosureSEC source: 0001127602-25-009725 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,493.074 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · balance_after: 96.204 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 20:44 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,056 | $9.45 | $95,063.39 |
DisclosureSEC source: 0001628280-25-007708 · wk-form4_1740516289.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 698,239 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 00:11 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,964 | $9.81 | $107,575.48 |
DisclosureSEC source: 0001628280-25-006516 · wk-form4_1740010306.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 708,295 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| October 23, 2024 Filed Oct 24, 2024 20:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 598,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-043632 · wk-form4_1729801556.xml · nonDerivative · entry 4 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,151,730 F1 · kind: Transfer without consideration for tax planning purposes. F4 · ownership.nature: The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. Read SEC document |
| October 23, 2024 Filed Oct 24, 2024 20:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 598,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-043632 · wk-form4_1729801556.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 598,270 F1 · kind: Transfer without consideration for tax planning purposes. F3 · ownership.nature: The shares are held by the spouse of the reporting person. Read SEC document |
| October 23, 2024 Filed Oct 24, 2024 20:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 598,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-043632 · wk-form4_1729801556.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,151,730 F1 · kind: Transfer without consideration for tax planning purposes. F2 · ownership.nature: The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. Read SEC document |
| October 23, 2024 Filed Oct 24, 2024 20:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 598,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-043632 · wk-form4_1729801556.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 719,259 F1 · kind: Transfer without consideration for tax planning purposes. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:21 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001104659-24-069666 · tm2416702-8_4seq1.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:17 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001628280-24-026219 · wk-form4_1717431464.xml · derivative · entry 6 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-05-29 Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:17 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-026219 · wk-form4_1717431464.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,989 Read SEC document |
| May 29, 2024 Filed May 31, 2024 14:50 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GiftCommon Stock | 3,443 | $145.48 | $500,887.64 |
DisclosureSEC source: 0001127602-24-017078 · form4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · George A. Scangos and Leslie S. Wilson Family Trust Disclosed balance after: 17,893 F2 · ownership.nature: Shares held in the George A. Scangos and Leslie S. Wilson Family Trust. Read SEC document |
| May 29, 2024 Filed May 31, 2024 14:50 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GiftCommon Stock | 3,443 | $145.48 | $500,887.64 |
DisclosureSEC source: 0001127602-24-017078 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,577.87 F1 · balance_after: 31.515 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 22:26 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,678 | $147.48 | $247,471.44 |
DisclosureSEC source: 0001127602-24-010687 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,989.355 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 126.437 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 00:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 17,722 | $11.65 | $206,521.55 |
DisclosureSEC source: 0001628280-24-006980 · wk-form4_1708993836.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,989 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 20, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.21 to $11.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 22, 2024 Filed Feb 27, 2024 00:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,028 | $10.05 | $100,737.28 |
DisclosureSEC source: 0001628280-24-006980 · wk-form4_1708993836.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,711 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 02:02 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 16,872 | $10.22 | $172,384.60 |
DisclosureSEC source: 0001628280-24-005747 · wk-form4_1708480944.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,739 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 20, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.07 to $10.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:02 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,878 | $10.24 | $111,386.37 |
DisclosureSEC source: 0001628280-24-005747 · wk-form4_1708480944.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,611 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| October 17, 2023 Filed Oct 18, 2023 18:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034571 · wk-form4_1697652863.xml · nonDerivative · entry 4 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,750,000 F1 · kind: Transfer without consideration for tax planning purposes. F4 · ownership.nature: The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. Read SEC document |
| October 17, 2023 Filed Oct 18, 2023 18:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034571 · wk-form4_1697652863.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Transfer without consideration for tax planning purposes. F3 · ownership.nature: The shares are held by the spouse of the reporting person. Read SEC document |
| October 17, 2023 Filed Oct 18, 2023 18:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034571 · wk-form4_1697652863.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,750,000 F1 · kind: Transfer without consideration for tax planning purposes. F2 · ownership.nature: The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. Read SEC document |
| October 17, 2023 Filed Oct 18, 2023 18:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034571 · wk-form4_1697652863.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,489 F1 · kind: Transfer without consideration for tax planning purposes. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 19:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 827,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049722 · doc4.xml · nonDerivative · entry 7 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Transfer without consideration for tax planning purposes. F7 · ownership.nature: The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 19:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 111,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049722 · doc4.xml · nonDerivative · entry 6 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Transfer without consideration for tax planning purposes. F6 · ownership.nature: The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 19:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 827,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049722 · doc4.xml · nonDerivative · entry 5 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Transfer without consideration for tax planning purposes. F5 · ownership.nature: The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 19:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 111,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049722 · doc4.xml · nonDerivative · entry 4 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Transfer without consideration for tax planning purposes. F4 · ownership.nature: The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 19:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049722 · doc4.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,750,000 F1 · kind: Transfer without consideration for tax planning purposes. F3 · ownership.nature: The shares are held by the spouse of the Reporting Person. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 19:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 1,750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049722 · doc4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,918,489 F1 · kind: Transfer without consideration for tax planning purposes. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 19:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 3,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049722 · doc4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 33,629 F1 · kind: Transfer without consideration for tax planning purposes. F2 · ownership.nature: The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 20:35 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0001104659-23-068920 · tm2317994-2_4seq1.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:15 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001104659-23-059224 · tm2315473-2_4seq1.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2033-05-09 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/16th of the shares of common stock underlying the option vesting upon the three-month anniversary of the Vesting Commencement Date and an additional 1/16th of the shares of common stock underlying the option vesting at the end of each successive three-month period thereafter, subject to the Reporting Person's continued service as a director. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:41 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,658 | $136.82 | $226,847.56 |
DisclosureSEC source: 0000899243-23-009227 · doc4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,184.918 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · balance_after: 107.055 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| February 24, 2023 Filed Feb 25, 2023 01:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,880 | $23.56 | $256,300.16 |
DisclosureSEC source: 0001209191-23-013004 · doc4.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,489 F2 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 29, 2022. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.215 to $24.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2023 Filed Feb 25, 2023 01:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,239 | $22.74 | $96,382.14 |
DisclosureSEC source: 0001209191-23-013004 · doc4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,369 F2 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 29, 2022. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.195 to $23.160 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 12,631 | $25.97 | $328,064.96 |
DisclosureSEC source: 0001209191-23-013004 · doc4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,608 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 00:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,474 | $28.80 | $186,451.20 |
DisclosureSEC source: 0001209191-23-011387 · doc4.xml · nonDerivative · entry 9 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,239 F9 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 29, 2022. F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.51 to $29.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 00:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 11,382 | $28.02 | $318,866.73 |
DisclosureSEC source: 0001209191-23-011387 · doc4.xml · nonDerivative · entry 8 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,713 F9 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 29, 2022. F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 00:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 9,894 | $25.29 | $250,199.47 |
DisclosureSEC source: 0001209191-23-011387 · doc4.xml · nonDerivative · entry 7 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,095 F8 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| January 18, 2023 Filed Feb 22, 2023 00:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 64,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011387 · doc4.xml · nonDerivative · entry 6 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 179,930 F1 · kind: Transfer without consideration for tax planning purposes. F7 · ownership.nature: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees. Read SEC document |
| January 18, 2023 Filed Feb 22, 2023 00:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 64,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011387 · doc4.xml · nonDerivative · entry 5 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,533,629 F1 · kind: Transfer without consideration for tax planning purposes. F6 · ownership.nature: The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011. Read SEC document |
| December 21, 2022 Filed Feb 22, 2023 00:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 49,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011387 · doc4.xml · nonDerivative · entry 4 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 111,644 F1 · kind: Transfer without consideration for tax planning purposes. F5 · ownership.nature: The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| December 21, 2022 Filed Feb 22, 2023 00:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 49,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011387 · doc4.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 827,151 F1 · kind: Transfer without consideration for tax planning purposes. F4 · ownership.nature: The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| December 21, 2022 Filed Feb 22, 2023 00:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 49,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011387 · doc4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 111,644 F1 · kind: Transfer without consideration for tax planning purposes. F3 · ownership.nature: The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| December 21, 2022 Filed Feb 22, 2023 00:29 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 49,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011387 · doc4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 827,151 F1 · kind: Transfer without consideration for tax planning purposes. F2 · ownership.nature: The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 21:12 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,785 | $136.82 | $244,223.70 |
DisclosureSEC source: 0001127602-22-010055 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,419.863 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · balance_after: 91.152 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. Read SEC document |
| March 10, 2022 Filed Apr 6, 2022 21:22 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 222,000 | $0.00 Strike: $29.48 | $0.00 |
DisclosureSEC source: 0001209191-22-023524 · doc4.xml · derivative · entry 8 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,000 Underlying: Common Stock · 222,000 shares Expires 2032-03-09 F8 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| March 10, 2022 Filed Apr 6, 2022 21:22 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 111,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023524 · doc4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,989 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.